If Gene Therapies Are so Revolutionary, Why Does No One Want to Pay for Them?

Key Takeaways

• Gene therapies often exceed $1 million per patient.
• Over 50% of new therapies face insurer coverage limits.
• Insurers pay upfront, but benefits accrue decades later.
• Medicaid CMMI model ties payment to outcomes, excludes commercial.
• Portability and spread‑out payments could align incentives, improve access.

Summary

Gene therapies promise one‑time cures for diseases like sickle‑cell and inherited blindness, but their price tags—often $1 million to $3 million per patient—clash with the U.S. insurance model. More than half of new cell and gene therapies face coverage restrictions because insurers must pay the full cost up front while benefits accrue over decades. A Medicaid outcomes‑based payment model launched in 2025 offers a glimpse of a solution, yet it excludes commercial insurers and does not address patient churn. Experts argue that payment portability and value‑based spreads are essential to unlock access.

Pulse Analysis

The past decade has seen a surge of gene‑editing products that promise one‑time cures for conditions ranging from sickle‑cell disease to inherited blindness. With nearly 50 FDA‑approved therapies and hundreds more in the pipeline, manufacturers price these treatments at $1 million to $3 million per patient, reflecting the high R&D outlays and the value of a permanent fix. While the clinical benefits are undeniable, the price structure collides with a fragmented U.S. insurance market, creating a financing gap that threatens to leave many breakthroughs on the shelf.

American insurers are forced to shoulder the full cost up‑front, yet the savings—fewer hospital stays, reduced drug use, and improved quality of life—materialize over many years and often fall to a different payer after a patient switches plans. This churn problem mirrors the hepatitis C pricing crisis of the 2010s, where short‑term budget cycles made high‑cost cures unattractive. In response, the Center for Medicare & Medicaid Innovation introduced an outcomes‑based model for Medicaid in early 2025, tying reimbursement to real‑world effectiveness, but the approach excludes commercial carriers and does not solve the portability issue.

Policymakers are now debating a suite of reforms: spreading payments over 10‑15 years, attaching obligations to patients rather than a single insurer, and adopting subscription‑style contracts that charge a per‑member fee for access to a portfolio of therapies. A national reinsurance pool could further dilute risk, allowing small insurers and state Medicaid programs to share costs while preserving incentives for innovation. By aligning financial responsibility with the long‑term health gains that gene therapies deliver, the United States can translate its billions of research dollars into tangible patient outcomes and avoid a generation of unaffordable miracles.